Equities Analysts Offer Predictions for TriMas Q3 Earnings

Key Points

• Analysts at Zacks Research have raised their Q3 2025 earnings estimate for TriMas Corporation, now expecting earnings of $0.57 per share, up from a previous estimate of $0.54.
• TriMas reported a net margin of 3.83% and a return on equity of 11.49%, with a quarterly revenue of $274.76 million, exceeding analysts' expectations.
• The consensus rating for TriMas stock is currently a "Buy" with a price target of $45.00, according to multiple analysts including KeyCorp and BWS Financial.

TriMas Corporation (NASDAQ:TRS - Free Report) - Research analysts at Zacks Research upped their Q3 2025 earnings per share (EPS) estimates for TriMas in a report issued on Tuesday, August 26th. Zacks Research analyst Team now anticipates that the industrial products company will post earnings of $0.57 per share for the quarter, up from their prior forecast of $0.54. The consensus estimate for TriMas' current full-year earnings is $1.69 per share. Zacks Research also issued estimates for TriMas' Q4 2025 earnings at $0.36 EPS, Q1 2026 earnings at $0.51 EPS, Q2 2026 earnings at $0.66 EPS, Q3 2026 earnings at $0.60 EPS, FY2026 earnings at $2.22 EPS, Q1 2027 earnings at $0.57 EPS and Q2 2027 earnings at $0.63 EPS.

TriMas (NASDAQ:TRS - Get Free Report) last issued its earnings results on Tuesday, July 29th. The industrial products company reported $0.61 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.11. TriMas had a return on equity of 11.49% and a net margin of 3.83%.The firm had revenue of $274.76 million for the quarter, compared to the consensus estimate of $251.18 million. During the same quarter in the previous year, the company posted $0.43 earnings per share. The business's quarterly revenue was up 14.2% compared to the same quarter last year. TriMas has set its FY 2025 guidance at 1.950-2.100 EPS.

A number of other research analysts also recently commented on TRS. KeyCorp set a $45.00 target price on TriMas and gave the company an "overweight" rating in a research note on Tuesday, August 12th. BWS Financial reiterated a "buy" rating and set a $45.00 price target (up previously from $40.00) on shares of TriMas in a research note on Wednesday, July 30th. Finally, Wall Street Zen upgraded TriMas from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $45.00.

TriMas Stock Down 0.3%

NASDAQ TRS traded down $0.10 on Friday, reaching $38.67. The stock had a trading volume of 499,103 shares, compared to its average volume of 550,682. The business has a 50 day moving average price of $33.07 and a 200 day moving average price of $27.05. The company has a current ratio of 2.59, a quick ratio of 1.44 and a debt-to-equity ratio of 0.59. TriMas has a 1 year low of $19.33 and a 1 year high of $39.09. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of 42.49 and a beta of 0.65.

TriMas Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 12th. Investors of record on Tuesday, August 5th were paid a dividend of $0.04 per share. The ex-dividend date was Tuesday, August 5th. This represents a $0.16 annualized dividend and a yield of 0.4%. TriMas's dividend payout ratio is presently 17.58%.

Insiders Place Their Bets

In other TriMas news, Director Adrianne Shapira bought 4,000 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The stock was purchased at an average price of $25.82 per share, for a total transaction of $103,280.00. Following the purchase, the director directly owned 8,476 shares in the company, valued at $218,850.32. This trade represents a 89.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders purchased 5,266 shares of company stock worth $137,188. 14.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TriMas

A number of hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN increased its holdings in TriMas by 21.1% during the 4th quarter. Wells Fargo & Company MN now owns 37,729 shares of the industrial products company's stock valued at $928,000 after purchasing an additional 6,573 shares in the last quarter. Barclays PLC increased its holdings in TriMas by 51.4% during the 4th quarter. Barclays PLC now owns 104,163 shares of the industrial products company's stock valued at $2,560,000 after purchasing an additional 35,371 shares in the last quarter. MetLife Investment Management LLC increased its holdings in TriMas by 5.9% during the 4th quarter. MetLife Investment Management LLC now owns 24,788 shares of the industrial products company's stock valued at $610,000 after purchasing an additional 1,378 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in TriMas by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,993 shares of the industrial products company's stock valued at $689,000 after purchasing an additional 2,703 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in TriMas during the 4th quarter valued at $1,602,000. 99.42% of the stock is owned by institutional investors and hedge funds.

TriMas Company Profile

TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.